	US 12,447,207 B2
	Human cytomegalovirus gB polypeptide
Yuhang Liu, South Glastonbury, CT (US); Ye Che, Niantic, CT (US); Xiaoyuan Sherry Chi, Tenafly, NJ (US); Philip Ralph Dormitzer, Sherborn, MA (US); Jennifer Anne Nicki, Gales Ferry, CT (US); and Xiaojie Yao, East Lyme, CT (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Nov. 10, 2023, as Appl. No. 18/506,578.
Application 18/506,578 is a continuation of application No. 17/350,008, filed on Jun. 17, 2021, granted, now 11,857,622.
Claims priority of provisional application 63/208,457, filed on Jun. 8, 2021.
Claims priority of provisional application 63/041,945, filed on Jun. 21, 2020.
Prior Publication US 2024/0100153 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/245 (2006.01); C07K 14/045 (2006.01); C12N 7/00 (2006.01)

CPC A61K 39/245 (2013.01) [C07K 14/045 (2013.01); C12N 7/00 (2013.01); C12N 2710/16134 (2013.01)]

20 Claims

1. A human cytomegalovirus (HCMV) immunogenic composition comprising: RNA formulated in a lipid nanoparticle,

wherein the RNA encodes an amino acid sequence for a glycoprotein B (gB) protein comprising at least one engineered disulfide mutation, wherein the gB protein comprises a cysteine mutation selected from the group consisting of: D217C, Y589C, M371C, W506C, N524C, and M684C, numbered according to SEQ ID NO:1.